New chemo delivery method targets pancreatic cancer before surgery
NCT ID NCT05634720
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests giving a single dose of chemotherapy directly into the liver artery before standard surgery and systemic chemo for localized pancreatic cancer. The goal is to see if this approach is safe and feasible in 20 patients. Researchers hope it may help prevent the cancer from spreading to the liver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hepatic artery chemotherapy (FUDR/oxaliplatin)
What this could lead to
If successful, this could point toward a new way to deliver chemotherapy directly to the liver before surgery, potentially reducing cancer spread in pancreatic cancer patients.
What could go wrong
This is a very small, early-stage safety study with only 20 participants. It is not designed to prove the treatment works, and there may be side effects from the chemotherapy or the procedure itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27710, United States